Argenx shares surge 30%
Argenx, an immunology company, experienced a significant boost in its shares, rising by 30% to reach $492.01. This increase follows the announcement of positive topline results from a study conducted in collaboration with biopharmaceutical company Zai Lab. The study evaluated the efficacy of Vyvgart Hytrulo, also known as efgartigimod alfa and hyaluronidase-qvfc, in adults suffering from chronic inflammatory demyelinating polyneuropathy.
Impressive performance and potential
The stock price for Argenx reached a 52-week high of $498.63 during the session, showcasing the company’s strong performance. Over the past 12 months, Argenx stock has seen a remarkable uptick, increasing by 35%. Additionally, Zai Lab’s shares rose by 8% to reach $30.17.
Encouraging study outcomes
The successful achievement of the study’s primary endpoint is an exciting development. The results clearly demonstrate that Vyvgart Hytrulo significantly lowers the risk of relapse compared to the placebo. Furthermore, the safety and tolerability profile of the treatment were consistent with previous findings, providing reassurance regarding its efficacy.
High patient participation and minimal side effects
An outstanding 91% of eligible patients chose to continue onto the next phase of the open-label extension study, highlighting their confidence in Vyvgart Hytrulo. Additionally, the occurrence of treatment-related adverse events, specifically injection site reactions, was relatively low compared to previous trials. All recorded injection site reactions were rated as mild to moderate and eventually resolved over time.
